Targets › NR1H3
1 program from 1 company in 4 trials: 2 Phase 2, 2 Phase 1; Gastroenterology, Metabolic and endocrine; next expected readout Dec 2026.
Nuclear receptor that exhibits a ligand-dependent transcriptional activation activity. Interaction with retinoic acid receptor (RXR) shifts RXR from its role as a silent DNA-binding partner to an active ligand-binding subunit in mediating retinoid responses through target genes defined by LXRES. LXRES are DR4-type response elements characterized by direct repeats of two similar hexanuclotide half-sites spaced by…. (UniProt, Q13133)
Open in Phaseline: the race on NR1H3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Eccogene | ECC4703 Thyroid hormone receptor beta isoform (THRβ) agonist | NR1H3 | Phase 2 | Adult Obesity; Metabolic Dysfunction-associated Steatohepatitis; Non-alcoholic Fatty Liver Disease (NAFLD); Metabolic Dysfunction-Associated Steatohepatitis | Dec 2026 |
Adult Obesity (1) Metabolic Dysfunction-associated Steatohepatitis (1) Non-alcoholic Fatty Liver Disease (NAFLD) (1) Metabolic Dysfunction-Associated Steatohepatitis (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.